Martin Vordermeier Selected Research

Bovine Tuberculosis

1/2022	Defined Antigen Skin Test for Bovine Tuberculosis Retains Specificity on Revaccination With Bacillus Calmette-Guérin.
1/2021	Detection of Mycobacterium tuberculosis complex DNA in CD34-positive peripheral blood mononuclear cells of asymptomatic tuberculosis contacts: an observational study.
1/2021	Identification and Phenotype of MAIT Cells in Cattle and Their Response to Bacterial Infections.
10/2020	Author Correction: Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis.
1/2020	Evaluating the sensitivity of the bovine BCG challenge model using a prime boost Ad85A vaccine regimen.
1/2020	A Defined Antigen Skin Test That Enables Implementation of BCG Vaccination for Control of Bovine Tuberculosis: Proof of Concept.
1/2020	Hydrophobic Mycobacterial Antigens Elicit Polyfunctional T Cells in Mycobacterium bovis Immunized Cattle: Association With Protection Against Challenge?
11/2019	Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis.
1/2016	Integrated computational prediction and experimental validation identifies promiscuous T cell epitopes in the proteome of Mycobacterium bovis.
5/2012	The influence of cattle breed on susceptibility to bovine tuberculosis in Ethiopia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Vordermeier Research Topics

Disease

20	Bovine Tuberculosis 01/2022 - 01/2006
14	Tuberculosis (Tuberculoses) 01/2021 - 04/2003
12	Infections 05/2022 - 04/2003
2	Bacterial Infections (Bacterial Infection) 01/2021 - 01/2010
2	Paratuberculosis (Johne's Disease) 10/2013 - 01/2006
2	Granuloma 01/2007 - 06/2006
1	Latent Tuberculosis 01/2021
1	HIV Infections (HIV Infection) 01/2021
1	Leprosy (Hansen's Disease) 01/2018
1	Latent Infection 01/2018
1	Leishmaniasis 01/2018
1	Melioidosis 01/2018
1	Inflammation (Inflammations) 11/2008
1	Necrosis 06/2006
1	Fibrosis (Cirrhosis) 06/2006

Drug/Important Bio-Agent (IBA)

12	AntigensIBA 05/2022 - 04/2003
9	VaccinesIBA 01/2021 - 06/2006
6	Tuberculin (PPD)IBA 11/2019 - 10/2007
6	Proteins (Proteins, Gene)FDA Link 03/2018 - 04/2003
3	Interferon-gamma (Interferon, gamma)IBA 01/2022 - 09/2006
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2018
3	Indicators and Reagents (Reagents)IBA 07/2011 - 07/2011
2	InterferonsIBA 01/2021 - 03/2010
2	BCG Vaccine FDA Link 10/2020 - 11/2019
2	Biological ProductsIBA 01/2020 - 01/2018
2	RNA (Ribonucleic Acid)IBA 01/2018 - 11/2004
2	Interleukin-6 (Interleukin 6)IBA 05/2012 - 03/2012
2	CytokinesIBA 03/2012 - 11/2008
2	Interleukin-10 (Interleukin 10)IBA 03/2012 - 11/2008
2	AcidsIBA 01/2007 - 06/2006
1	Isoniazid (Ftivazide)FDA LinkGeneric 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	PerforinIBA 01/2021
1	LigandsIBA 01/2021
1	Subunit VaccinesIBA 01/2020
1	LipopeptidesIBA 01/2020
1	bis(p-chlorophenyl)acetic acid (DDA)IBA 10/2013
1	Interleukin-12 (IL 12)IBA 03/2012
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2012
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2010
1	AntibodiesIBA 09/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2008
1	Interleukin-4 (Interleukin 4)IBA 11/2008
1	SolutionsIBA 07/2006
1	Transforming Growth Factor beta (TGF-beta)IBA 06/2006
1	EpitopesIBA 01/2006
1	Peptides (Polypeptides)IBA 04/2003
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 04/2003

Therapy/Procedure

1	Therapeutics 01/2021
1	Aftercare (After-Treatment) 01/2021